Zuellig Pharma Specialty Solutions (India) Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 19-12-2024
- Paid Up Capital ₹ 3.94 M
as on 19-12-2024
- Company Age 9 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Revenue -31.96%
(FY 2022)
- Profit -25.45%
(FY 2022)
- Ebitda -39.61%
(FY 2022)
- Net Worth 10.33%
(FY 2022)
- Total Assets -9.83%
(FY 2022)
About Zuellig Pharma Specialty Solutions (India)
The Company is engaged in the Transport And Logistics Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 3.94 M, as per Ministry of Corporate Affairs (MCA) records.
Chee Lim, Evasio Barbero, Dharmesh Parikh, and One other member serve as directors at the Company.
- CIN/LLPIN
U74120MH2015FTC262353
- Company No.
262353
- Company Classification
Private Limited Foreign Company Incorporated In India
- Incorporation Date
02 Mar 2015
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Zuellig Pharma Specialty Solutions (India)?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Giuseppe Leo  | Director | 03-Mar-2015 | Current |
| Chee Lim | Director | 21-Feb-2023 | Current |
Evasio Barbero  | Director | 14-Jan-2022 | Current |
Dharmesh Parikh  | Director | 16-Jul-2021 | Current |
Financial Performance of Zuellig Pharma Specialty Solutions (India).
Zuellig Pharma Specialty Solutions (India) Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 31.96% decrease. The company also saw a substantial fall in profitability, with a 25.45% decrease in profit. The company's net worth Soared by an impressive increase of 10.33%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Zuellig Pharma Specialty Solutions (India)?
In 2022, Zuellig Pharma Specialty Solutions (India) had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Zuellig Pharma Specialty Solutions (India)?
Unlock and access historical data on people associated with Zuellig Pharma Specialty Solutions (India), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Zuellig Pharma Specialty Solutions (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Zuellig Pharma Specialty Solutions (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
